inositol has been researched along with Polycystic Ovarian Syndrome in 205 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effect of myo-inositol and d-chiro-inositol in combination (MI + DCI) with combined hormonal contraceptive (CHC) on menstrual cycle regulation in young Indian women with polycystic ovary syndrome (PCOS)." | 9.51 | Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study. ( Bhatla, N; Kachhawa, G; Khadgawat, R; Kulshrestha, V; Mahey, R; Senthil Kumar, KV, 2022) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 9.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "Metformin is the gold standard insulin sensitizer, which is widely used to treat insulin resistance in polycystic ovary syndrome (PCOS)." | 9.41 | Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Ács, N; Greff, D; Hegyi, P; Horváth, EM; Juhász, AE; Nyirády, P; Park, S; Sipos, Z; Szinte, J; Váncsa, S; Váradi, A; Várbíró, S, 2023) |
| "This investigation was conducted to evaluate comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome (PCOS)." | 9.30 | Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Foroozanfard, F; Ghaderi, A; Shokrpour, M; Vahedpoor, Z, 2019) |
| "To evaluate whether 4 gram myoinositol and 400 mcg folic acid(MYO) therapy has any effects on ovarian stromal blood flow by using pulsed and color Doppler at 3 months follow-up period in polycystic ovary syndrome (PCOS)." | 9.30 | The effect of myoinositol on ovarian blood flows in women with polycystic ovary syndrome. ( Emekçi Özay, Ö; Gülekli, B; Okyay, RE; Özay, AC, 2019) |
| "The purpose is a comparison of effectiveness of myo-inositol and metformin in infertile women with polycystic ovary syndrome (PCOS) treated with letrozole." | 9.30 | The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. ( Bazarganipour, F; Kutenaee, MA; Pourghasem, S; Taghavi, SA, 2019) |
| "Data on comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in subjects with polycystic ovary syndrome (PCOS) are scarce." | 9.27 | Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Asemi, Z; Bahmani, F; Foroozanfard, F; Jamilian, H; Jamilian, M, 2018) |
| "To our knowledge, data on comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in subjects with polycystic ovary syndrome (PCOS) are limited." | 9.24 | Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Badehnoosh, B; Bahmani, F; Farhat, P; Foroozanfard, F; Jamilian, H; Jamilian, M, 2017) |
| "Objectıve: The aim of the study is to investigate the effect of myo-inositol (MYO) on pregnancy rates of patients diagnosed with polycystic ovary syndrome (PCOS) who undergone controlled ovulation induction and intrauterine insemination (IUI)." | 9.24 | Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. ( Çağlıyan, E; Emekçi Özay, Ö; Gülekli, B; Okyay, RE; Özay, AC, 2017) |
| "This meta-analysis aims to perform an updated meta-analysis to evaluate myo-inositol (myo-ins) and the classical insulin sensitizer metformin in terms of efficacy and safety for treating women with polycystic ovary syndrome (PCOS)." | 9.22 | Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. ( He, B; Xing, C; Zhang, JQ, 2022) |
| "The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance." | 9.20 | Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. ( Carlomagno, G; Gateva, A; Genazzani, AD; Kamenov, Z; Kolarov, G, 2015) |
| "To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients." | 9.17 | Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. ( Artini, PG; Cela, V; Di Berardino, OM; Genazzani, AD; Papini, F; Ruggiero, M; Simi, G, 2013) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "Compare the effects of a combined contraceptive pill (OCP) in combination with myo-inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic ovary syndrome (PCOS)." | 9.15 | The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. ( Costantino, D; Guaraldi, C; Minozzi, M; Unfer, V, 2011) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 9.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| " Therefore, our primary aim is to investigate the proper understanding of endocrine disruption during PCOS and secondary to the therapeutic potential of inositol in reestablishing the equilibrium of ovarian dysfunction, anovulation, and eventually infertility." | 9.12 | A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome. ( Almalki, WH, 2021) |
| "Recent studies have revealed that myo-inositol could be more influential in patients with polycystic ovary syndrome (PCOS)." | 9.12 | The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. ( Azizi Kutenaei, M; Eini, F; Ghaemmaghami, P; Hosseini Teshnizi, S; Roozbeh, N, 2021) |
| "Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia, possibly because of a deficiency of a D-chiro-inositol-containing phosphoglycan that mediates the action of insulin." | 9.09 | Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. ( Allan, G; Gunn, RD; Jakubowicz, DJ; Nestler, JE; Reamer, P, 1999) |
| "Metformin (MET), the most commonly used insulin sensitizer, is the reference off-label drug for the treatment of polycystic ovary syndrome (PCOS), worldwide." | 9.01 | Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. ( Facchinetti, F; Grandi, G; Orrù, B; Unfer, V, 2019) |
| "Inositols improve menstrual cycles, ovulation and metabolic changes in polycystic ovary syndrome." | 8.98 | Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( Bhide, P; Coomarasamy, A; Psaroudakis, D; Pundir, J; Sabatini, L; Savnur, P; Teede, H; Thangaratinam, S, 2018) |
| "The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM)." | 8.98 | The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. ( Gateva, A; Kamenov, Z; Unfer, V, 2018) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "During the last decades, a substantial body of research has focused on the role of the two major inositol (Ins) stereoisomers, myoinositol (myoIns) and D-chiroinositol (D-chiroIns), both second messengers of insulin, in insulin-dependent processes, including polycystic ovary syndrome (PCOS)." | 8.93 | Physiological role and clinical utility of inositols in polycystic ovary syndrome. ( Bevilacqua, A; Bizzarri, M, 2016) |
| "Inositol acts as a second messenger in insulin signaling pathway Literature data suggest inositol deficiency in insulin-resistant women with the polycystic ovary syndrome." | 8.90 | [The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders]. ( Jakimiuk, AJ; Szamatowicz, J, 2014) |
| "Presentation of a comprehensive body of knowledge on the role of insulin sensitizer myo-inositol in the treatment of polycystic ovary syndrome (PCOS)." | 8.90 | [Myo-inositol in the treatment of polycystic ovary syndrome]. ( Křepelka, P, 2014) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 8.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 8.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| "Metformin is an effective treatment for anovulation in women with PCOS." | 8.82 | Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "Myo-inositol supplementation may reduce insulin resistance (IR) with few serious side effects in patients with polycystic ovary syndrome (PCOS)." | 7.96 | Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. ( Chen, X; Li, C; Zhang, W; Zhang, Y; Zheng, X, 2020) |
| "The aim of this retrospective study was to evaluate the effects of a long-term treatment with α-lipoic acid (ALA) combined with myo-inositol (MI) on clinical and metabolic features of women with polycystic ovary syndrome (PCOS)." | 7.96 | Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. ( Fidecicchi, T; Fruzzetti, F; Gambacciani, M; Palla, G, 2020) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 7.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| "Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1." | 7.91 | Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. ( Alibrandi, A; Benvenga, S; Le Donne, M; Metro, D; Papa, M, 2019) |
| "Polycystic ovary syndrome (PCOS)is a gynecological endocrine disorder which is associated with systemic inflammatory status inducing red blood cells (RBC) membrane alterations related to insulin resistance and testosterone levels which could be greatly improved by myo-inositol (MYO) uptake." | 7.88 | Ameliorative effect of myo-inositol on red blood cell alterations in polycystic ovary syndrome: in vitro study. ( Ambrosini, G; Andrisani, A; Armanini, D; Bordin, L; Bosello Travain, V; Brunati, AM; Dessole, F; Donà, G; Marin, L; Ragazzi, E; Sabbadin, C; Tibaldi, E, 2018) |
| "Authors would like to demonstrate the beneficial effect of myo-inositol supplementation in a pregnant woman with insulin-dependent type 2 diabetes mellitus and polycystic ovary syndrome." | 7.85 | [The myo-inositol is beneficial in the therapy of pregnancy with insulin-dependent type 2 diabetes and polycystic ovary syndrome]. ( Kun, A; Tornóczky, J, 2017) |
| "The aim of our study was to investigate the effects of a combined treatment with alpha-lipoic acid (ALA) and myoinositol (MYO) on clinical, endocrine and metabolic features of women affected by polycystic ovary syndrome (PCOS)." | 7.85 | Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. ( Apa, R; De Cicco, S; Della Casa, S; Di Florio, C; Immediata, V; Lanzone, A; Policola, C; Romualdi, D; Scarinci, E; Tagliaferri, V; Tropea, A, 2017) |
| "To evaluate the effects of D-Chiro-Inositol in women affected by polycystic ovary syndrome (PCOS)." | 7.81 | Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. ( Barbaro, L; Laganà, AS; Pizzo, A, 2015) |
| "In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d-chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ovary syndrome." | 7.81 | Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. ( Benvenga, S; Bevilacqua, A; Bizzarri, M; Carlomagno, G; Cavalli, P; Chiu, TT; D'Anna, R; Devroey, P; Di Renzo, GC; Facchinetti, F; Gerli, S; Hod, M; Kamenov, ZA; Lanzone, A; Oliva, MM; Soulage, C, 2015) |
| "Previous studies from our and other labs have shown that insulin resistance is associated with an inositol imbalance of excess myo-inositol and deficient chiro-inositol together with a deficiency of myo-inositol to chiro-inositol epimerase in vivo and in vitro." | 7.80 | Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. ( Heimark, D; Larner, J; McAllister, J, 2014) |
| "To investigate hormonal dynamics in a group of non-obese polycystic ovary syndrome (PCOS) patients under myo-inositol (MYO) administration." | 7.80 | Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. ( Campedelli, A; Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2014) |
| "The results of this study demonstrated a good efficacy of both treatments, although in the group treated with the combination of myo-inositol/monacolin K improvement in lipids and hyperandrogenism were significantly better." | 7.79 | [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women]. ( Cappelli, V; De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC, 2013) |
| "In an attempt to evaluate the role of inositol supplementation in insulin-resistant patients with polycystic ovary syndrome (PCOS), undergoing gonadotropin ovulation induction using the low-dose step-down regimen, we conducted a prospective longitudinal study comparing the stimulation characteristics of 15 patients treated with inositol, to a cohort, matched by age and body mass index (BMI), without inositol." | 7.77 | The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Orvieto, R, 2011) |
| "To evaluate the labeling accuracy of four myo-inositol products, designed for polycystic ovary syndrome (PCOS) treatment, available on the italian market and to perform a cost comparison based on myo-inositol content in milligrams for products analyzed." | 7.77 | Myo-inositol products in polycystic ovary syndrome (PCOS) treatment: quality, labeling accuracy, and cost comparison. ( De Michele, F; Molgora, M; Papaleo, E; Pellegrino, M; Quaranta, L, 2011) |
| " Increased clearance of inositols might reduce tissue availability of DCI and decrease the release of DCI-IPG mediator, which could contribute to insulin resistance and compensatory hyperinsulinemia in Greek women, as previously described in American women." | 7.74 | Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. ( Apridonidze, T; Baillargeon, JP; Diamanti-Kandarakis, E; Nestler, JE; Ostlund, RE, 2008) |
| "To assess this possibility in polycystic ovary syndrome (PCOS), we determined insulin sensitivity (Si by frequently sampled intravenous glucose tolerance test), plasma and urinary DCI and myo-inositol (MYO) levels (by gas chromatography/mass spectrometry), and the release of insulin and DCI-IPG during the oral glucose tolerance test (area under the curve [AUC]) in 23 women with PCOS and 26 normal women." | 7.73 | Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Diamanti-Kandarakis, E; Iuorno, MJ; Nestler, JE; Ostlund, RE, 2006) |
| "D-chiro-inositol (DCI) is a drug candidate for the treatment of type 2 diabetes and polycystic ovary syndrome, since it improves the efficiency with which the body uses insulin and also promotes ovulation." | 7.73 | Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. ( Ashida, H; Ikeuchi, M; Kinehara, M; Morinaga, T; Yamaguchi, M; Yoshida, K, 2006) |
| "To determine whether insulin stimulates human ovarian testosterone production in the polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system, thecal cells from polycystic ovary syndrome women were isolated and cultured." | 7.70 | Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. ( Brik, C; de Vargas, AF; Jakubowicz, DJ; Medina, F; Nestler, JE; Quintero, N, 1998) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 6.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| "Pregnancy is similarly characterized by substantial and complex changes in glycemic and lipidomic regulation as part of maternal adaptation and is also associated with physiological alterations in inositol processing." | 6.82 | A review of the role of inositols in conditions of insulin dysregulation and in uncomplicated and pathological pregnancy. ( Chan, SY; Sharma, N; Watkins, OC; Yong, HEJ, 2022) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 6.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "Myo-inositol is a simple and safe treatment that is capable of restoring spontaneous ovarian activity and consequently fertility in most patients with PCOS." | 6.73 | Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. ( Baillargeon, JP; Brigante, C; Cino, I; De Santis, L; Ferrari, A; Fusi, F; Marelli, G; Papaleo, E; Redaelli, A; Unfer, V, 2007) |
| "These activities allow a treatment for polycystic ovary syndrome (PCOS) to be defined based on the combined administration of MI and DCI, where the best MI:DCI ratio is 40:1." | 6.66 | Inositols in Polycystic Ovary Syndrome: An Overview on the Advances. ( Dewailly, D; Diamanti-Kandarakis, E; Facchinetti, F; Kamenov, ZA; Laganà, AS; Nestler, JE; Soulage, CO; Unfer, V, 2020) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 6.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| "To compare the effect of myo-inositol and d-chiro-inositol in combination (MI + DCI) with combined hormonal contraceptive (CHC) on menstrual cycle regulation in young Indian women with polycystic ovary syndrome (PCOS)." | 5.51 | Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study. ( Bhatla, N; Kachhawa, G; Khadgawat, R; Kulshrestha, V; Mahey, R; Senthil Kumar, KV, 2022) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 5.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 5.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "Metformin is the gold standard insulin sensitizer, which is widely used to treat insulin resistance in polycystic ovary syndrome (PCOS)." | 5.41 | Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Ács, N; Greff, D; Hegyi, P; Horváth, EM; Juhász, AE; Nyirády, P; Park, S; Sipos, Z; Szinte, J; Váncsa, S; Váradi, A; Várbíró, S, 2023) |
| "To evaluate the benefits of myoinositol plus metformin versus myoinositol alone in infertile polycystic ovarian syndrome (PCOS) women undergoing ovulation induction cycles." | 5.41 | Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial. ( Bhatla, N; Gupta, M; Kachhawa, G; Khadgawat, R; Kumari, R; Mahey, R; Prabhakar, P; Sharma, JB; Vanamail, P, 2021) |
| "Inositol is a physiological compound belonging to the sugar family." | 5.40 | Inositol: history of an effective therapy for Polycystic Ovary Syndrome. ( Bizzarri, M; Carlomagno, G, 2014) |
| "Inositol is a polyalcohol existing as nine different stereoisomers, two of which have been shown to be insulin mediators: myo-inositol (MI) and D-chiro-inositol (DCI)." | 5.37 | Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction. ( Galletta, M; Grasso, S; Roseff, SJ; Vaiarelli, A, 2011) |
| "Polycystic ovary syndrome is the most common cause of chronic anovulation infertility in women in fertile period." | 5.36 | [Effects of inositol on oocyte quality in patients affected with polycystic ovary syndrome]. ( Carbonaro, A; Ciotta, L; Gulino, F; Pagano, I; Palumbo, M; Stracquadanio, M, 2010) |
| "This investigation was conducted to evaluate comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome (PCOS)." | 5.30 | Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Foroozanfard, F; Ghaderi, A; Shokrpour, M; Vahedpoor, Z, 2019) |
| "The present study was planned to evaluate the benefit of synergetic effect of Metformin plus Myo-inositol versus Metformin alone in infertile polycystic ovarian syndrome (PCOS) women undergoing ovulation induction." | 5.30 | Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. ( Agrawal, A; Kachhawa, G; Khadgawat, R; Kriplani, A; Mahey, R; Vanamail, P, 2019) |
| "To evaluate whether 4 gram myoinositol and 400 mcg folic acid(MYO) therapy has any effects on ovarian stromal blood flow by using pulsed and color Doppler at 3 months follow-up period in polycystic ovary syndrome (PCOS)." | 5.30 | The effect of myoinositol on ovarian blood flows in women with polycystic ovary syndrome. ( Emekçi Özay, Ö; Gülekli, B; Okyay, RE; Özay, AC, 2019) |
| "The purpose is a comparison of effectiveness of myo-inositol and metformin in infertile women with polycystic ovary syndrome (PCOS) treated with letrozole." | 5.30 | The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. ( Bazarganipour, F; Kutenaee, MA; Pourghasem, S; Taghavi, SA, 2019) |
| "The aim of this clinical trial was to evaluate the efficacy of seven different ratios between two inositols stereoisomers, myo-inositol (MI) and D-chiro-inositol (DCI), in the therapy of polycystic ovary syndrome (PCOS)." | 5.30 | The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. ( Basciani, S; Camajani, E; Nordio, M, 2019) |
| "Data on comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in subjects with polycystic ovary syndrome (PCOS) are scarce." | 5.27 | Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Asemi, Z; Bahmani, F; Foroozanfard, F; Jamilian, H; Jamilian, M, 2018) |
| "Myo-inositol (MI), successfully used in polycystic ovary syndrome (PCOS), was administered with α-LA to exploit its action of favouring the passage of other molecules through biological barriers, and also considering its anti-inflammatory effect." | 5.27 | Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. ( Buonomo, G; Calcagno, M; Montanino Oliva, M; Unfer, V, 2018) |
| "To our knowledge, data on comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in subjects with polycystic ovary syndrome (PCOS) are limited." | 5.24 | Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Badehnoosh, B; Bahmani, F; Farhat, P; Foroozanfard, F; Jamilian, H; Jamilian, M, 2017) |
| "It was previously shown that higher concentrations of myo-inositol in human follicular fluid improve oocyte and embryo quality, whereas D-chiro-inositol seems to worsen oocyte quality and ovarian response in polycystic ovary syndrome patients." | 5.24 | Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? ( Goudakou, M; Monastra, G; Pavlidou, T; Prapas, N; Ravanos, K, 2017) |
| "Objectıve: The aim of the study is to investigate the effect of myo-inositol (MYO) on pregnancy rates of patients diagnosed with polycystic ovary syndrome (PCOS) who undergone controlled ovulation induction and intrauterine insemination (IUI)." | 5.24 | Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. ( Çağlıyan, E; Emekçi Özay, Ö; Gülekli, B; Okyay, RE; Özay, AC, 2017) |
| " Among PCOS women undergoing assisted reproductive technology, treatment based on myo-inositol and high doses of D-chiro-inositol has been shown to increase pregnancy rate and number of live births, reduce ovarian hyperstimulation syndrome and improve oocyte quality." | 5.22 | Strategy to improve the female fertility in the general gynecologist's office: use of a nutritional supplement based on myo-inositol/D-chiro-inositol and antioxidants. ( Losa, F; Mendoza, N; Palacios, S, 2022) |
| "This meta-analysis aims to perform an updated meta-analysis to evaluate myo-inositol (myo-ins) and the classical insulin sensitizer metformin in terms of efficacy and safety for treating women with polycystic ovary syndrome (PCOS)." | 5.22 | Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. ( He, B; Xing, C; Zhang, JQ, 2022) |
| " Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis." | 5.22 | Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. ( Deshpande, S; Gajjar, N; Jethaliya, H; Patel, R; Patel, V, 2022) |
| "To date, the involvement of α-Lactalbumin (α-LA) in the management of polycystic ovary syndrome (PCOS) refers to its ability to improve intestinal absorption of natural molecules like inositols, overcoming the inositol resistance." | 5.22 | Positive Effects of α-Lactalbumin in the Management of Symptoms of Polycystic Ovary Syndrome. ( Artale, S; Basciani, S; Bizzarri, M; Cardinale, V; Lepore, E; Nordio, M; Unfer, V, 2022) |
| "The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance." | 5.20 | Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. ( Carlomagno, G; Gateva, A; Genazzani, AD; Kamenov, Z; Kolarov, G, 2015) |
| "Our study showed that both myo-inositol (MI-PG) and D-chiro inositol (DCI-PG) treatments are able to significantly improve the regularity of the menstrual cycle, the Acne Score, the endocrine and metabolic parameters and the insulin-resistence in young, overweight, PCOS patients." | 5.20 | Myo-inositol vs. D-chiro inositol in PCOS treatment. ( Ciotta, L; Formuso, C; Stracquadanio, M, 2015) |
| "This new myo-inositol, monacolin K and lipoic acid association contains appropriate substances to contrast various etiopathogenic elements responsible for the onset of PCOS and the symptoms of hyperandrogenism and dyslipidemia related to it." | 5.20 | Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. ( Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015) |
| "Myo-inositol and D-chiro-inositol are capable of improving the ovarian function and metabolism of polycystic ovary syndrome (PCOS) patients." | 5.19 | Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. ( Barbaro, L; Laganà, AS; Pizzo, A, 2014) |
| " Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26)." | 5.19 | Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. ( Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Santagni, S; Simoncini, T, 2014) |
| " Aim of the study was to evaluate the efficacy of natural substances such as inositol and glucomannan, and their combination in reducing glucose levels and improving insulin sensitivity in PCOS patients." | 5.19 | [Combination inositol and glucomannan in PCOS patients]. ( Cappelli, V; Cianci, EA; De Leo, V; Morgante, G; Tosti, C, 2014) |
| "Polycystic ovary syndrome (PCOS) women undergoing IVF-ET were treated with myo-inositol combined with D-chiro-inositol in the physiological ratio (1." | 5.17 | The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. ( Bevilacqua, A; Colazingari, S; Najjar, R; Treglia, M, 2013) |
| "To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients." | 5.17 | Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. ( Artini, PG; Cela, V; Di Berardino, OM; Genazzani, AD; Papini, F; Ruggiero, M; Simi, G, 2013) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| " The effectiveness in reducing the risk of metabolic syndrome as well as in enhancing the ovarian functions of a combined therapy with MI and DCI was compared to a mono therapy in a randomized controlled trial." | 5.16 | The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. ( Nordio, M; Proietti, E, 2012) |
| "Compare the effects of a combined contraceptive pill (OCP) in combination with myo-inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic ovary syndrome (PCOS)." | 5.15 | The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. ( Costantino, D; Guaraldi, C; Minozzi, M; Unfer, V, 2011) |
| "The aim of this study is to determine the effects of myo-inositol on oocyte's quality on a sample of women with polycystic ovary syndrome." | 5.15 | Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. ( Carbonaro, A; Ciotta, L; Gulino, F; Pagano, I; Palumbo, M; Stracquadanio, M, 2011) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 5.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| "The aim of this study was to compare the effectiveness of myo-inositol (MYO) and metformin, in monotherapy or in association with recombinant follicle stimulating hormone (r-FSH), in the treatment of menstrual irregularities, chronic anovulation, and female infertility in patients with polycystic ovary syndrome (PCOS)." | 5.14 | Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. ( Benedetto, V; Raffone, E; Rizzo, P, 2010) |
| "To determine the effects of myo-inositol on oocyte quality in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI) cycles." | 5.14 | Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. ( Baillargeon, JP; De Santis, L; Fusi, F; Occhi, F; Papaleo, E; Unfer, V, 2009) |
| "We reviewed current literature in different databases, searching for D-chiro-Inositol in relation with one of the following keywords: myo-inositol, PCOS, infertility, insulin resistance, aromatase, androgen and inositol, testosterone, estrogen and inositol, estradiol, hypogonadotropic hypogonadism, fat tissue, estrogens and cancer, anovulation, uterine myoma, endometriosis, endometrial hyperplasia." | 5.12 | The use of D-chiro-Inositol in clinical practice. ( Aragona, C; Bevilacqua, A; Bizzarri, M; Forte, G; Gambioli, R; Unfer, V, 2021) |
| " Therefore, our primary aim is to investigate the proper understanding of endocrine disruption during PCOS and secondary to the therapeutic potential of inositol in reestablishing the equilibrium of ovarian dysfunction, anovulation, and eventually infertility." | 5.12 | A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome. ( Almalki, WH, 2021) |
| "Recent studies have revealed that myo-inositol could be more influential in patients with polycystic ovary syndrome (PCOS)." | 5.12 | The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. ( Azizi Kutenaei, M; Eini, F; Ghaemmaghami, P; Hosseini Teshnizi, S; Roozbeh, N, 2021) |
| "Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone." | 5.12 | Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. ( He, B; Xing, C; Zhang, J; Zhao, H, 2021) |
| "Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia, possibly because of a deficiency of a D-chiro-inositol-containing phosphoglycan that mediates the action of insulin." | 5.09 | Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. ( Allan, G; Gunn, RD; Jakubowicz, DJ; Nestler, JE; Reamer, P, 1999) |
| "It is well known that myo-inositol (MI) and D-chiro-inositol (DCI) are insulin-sensitizing agents, and MI is of proven utility in polycystic ovary syndrome (PCOS)." | 5.05 | Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART). ( Dewailly, D; Espinola, MSB; Facchinetti, F; Ozay, AC; Prapas, N; Unfer, V; Vazquez-Levin, M; Wdowiak, A, 2020) |
| "Metformin (MET), the most commonly used insulin sensitizer, is the reference off-label drug for the treatment of polycystic ovary syndrome (PCOS), worldwide." | 5.01 | Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. ( Facchinetti, F; Grandi, G; Orrù, B; Unfer, V, 2019) |
| "There is insufficient evidence for an effect of inositols on ovarian reserve markers and to support their use as pretreatment before IVF/ICSI in women with polycystic ovary syndrome." | 5.01 | The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis. ( Acharya, G; Bhide, P; Gudi, A; Homburg, R; Pundir, J; Shah, A, 2019) |
| "Inositols improve menstrual cycles, ovulation and metabolic changes in polycystic ovary syndrome." | 4.98 | Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( Bhide, P; Coomarasamy, A; Psaroudakis, D; Pundir, J; Sabatini, L; Savnur, P; Teede, H; Thangaratinam, S, 2018) |
| "The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM)." | 4.98 | The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. ( Gateva, A; Kamenov, Z; Unfer, V, 2018) |
| "Introduction The use of 2 × 2000 mg myo-inositol +2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with polycystic ovary syndrome (PCOS)." | 4.98 | Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. ( Druckman, R; Lesoine, B; Regidor, PA; Schindler, AE, 2018) |
| "To evaluate whether oral myo-inositol supplementation (MI) is able to reduce the amount of gonadotropins (GA) and the length of controlled ovarian hyperstimulation (SL) in both Polycystic Ovarian Syndrome (PCOS) and non-PCOS women undergoing in vitro fertilization (IVF)." | 4.98 | Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. ( Ambrosini, G; D'Anna, R; Laganà, AS; Noventa, M; Vitagliano, A, 2018) |
| " The vast majority of published data on insulin sensitizing PCOS treatments are reported in adult women; these have included weight loss, metformin, thiazolidinediones, and the inositols." | 4.95 | Insulin sensitizers in adolescents with polycystic ovary syndrome. ( LE, TN; Nestler, JE; Wickham, EP, 2017) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "During the last decades, a substantial body of research has focused on the role of the two major inositol (Ins) stereoisomers, myoinositol (myoIns) and D-chiroinositol (D-chiroIns), both second messengers of insulin, in insulin-dependent processes, including polycystic ovary syndrome (PCOS)." | 4.93 | Physiological role and clinical utility of inositols in polycystic ovary syndrome. ( Bevilacqua, A; Bizzarri, M, 2016) |
| "Inositol acts as a second messenger in insulin signaling pathway Literature data suggest inositol deficiency in insulin-resistant women with the polycystic ovary syndrome." | 4.90 | [The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders]. ( Jakimiuk, AJ; Szamatowicz, J, 2014) |
| "Presentation of a comprehensive body of knowledge on the role of insulin sensitizer myo-inositol in the treatment of polycystic ovary syndrome (PCOS)." | 4.90 | [Myo-inositol in the treatment of polycystic ovary syndrome]. ( Křepelka, P, 2014) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 4.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 4.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| "Metformin is an effective treatment for anovulation in women with PCOS." | 4.82 | Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "Accumulating evidence suggests that oral supplementation with myo-Inositol (myo-Ins) is able to reduce the amount of gonadotropins and days of controlled ovarian hyperstimulation (COS) necessary to achieve adequate oocyte maturation in assisted reproduction technology (ART) protocols, particularly in women affected by polycystic ovary syndrome (PCOS)." | 4.31 | A Markov-model simulation of IVF programs for PCOS patients indicates that coupling myo-Inositol with rFSH is cost-effective for the Italian Health System. ( Aragona, C; Beresniak, A; Chiantera, V; Forte, G; Laganà, AS; Oliva, MM; Russo, M; Unfer, V, 2023) |
| "The aim of this work was to evaluate the effect of a comprehensive method of pre-pregnancy pre-treatment which includes a vitamin complex with inositol and vitamin D3, on the levels of pituitary and ovarian hormones in women with infertility against the background of polycystic ovary syndrome." | 4.12 | Hormonal profile in women with infertility against the background of polycystic ovary syndrome depending on the type of pre-pregnancy pre-treatment. ( Halnykina, S; Khmil Doswald, A; Khmil, M; Khmil, S, 2022) |
| "Administration of 1000-1500 mg/day D-Chiro-Inositol (DCIns) or a combination of Myo-Inositol (MyoIns) and DCIns in their plasma molar ratio (40:1) for three or more months are among recommended treatments for metabolic syndrome and/or Polycystic Ovary Syndrome (PCOS)." | 4.02 | High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. ( Bevilacqua, A; Di Emidio, G; Dragotto, J; Lucarelli, M; Monastra, G; Tatone, C, 2021) |
| " In the last years, among the insulin sensitizers, the use of the two active isoforms of inositols (myo-inositol and d-chiro-inositol) has been spreading for the treatment of PCOS insulin resistance." | 4.02 | The relevance of inositols treatment for PCOS before and during ART. ( Artini, PG; Genazzani, AD; Malacarne, E; Tomatis, V, 2021) |
| "Myo-inositol supplementation may reduce insulin resistance (IR) with few serious side effects in patients with polycystic ovary syndrome (PCOS)." | 3.96 | Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. ( Chen, X; Li, C; Zhang, W; Zhang, Y; Zheng, X, 2020) |
| "The aim of this retrospective study was to evaluate the effects of a long-term treatment with α-lipoic acid (ALA) combined with myo-inositol (MI) on clinical and metabolic features of women with polycystic ovary syndrome (PCOS)." | 3.96 | Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. ( Fidecicchi, T; Fruzzetti, F; Gambacciani, M; Palla, G, 2020) |
| "The aim of the study is to investigate the efficacy of a treatment with myoinositol plus L-tyrosine, selenium, and chromium in women with polycystic ovarian syndrome (PCOS)." | 3.91 | Efficacy of the synergic action of myoinositol, tyrosine, selenium and chromium in women with PCOS. ( Carra, MC; Lippa, A; Lisi, F; Montanino Oliva, M; Zuev, V, 2019) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 3.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| "Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1." | 3.91 | Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. ( Alibrandi, A; Benvenga, S; Le Donne, M; Metro, D; Papa, M, 2019) |
| "Polycystic ovary syndrome (PCOS)is a gynecological endocrine disorder which is associated with systemic inflammatory status inducing red blood cells (RBC) membrane alterations related to insulin resistance and testosterone levels which could be greatly improved by myo-inositol (MYO) uptake." | 3.88 | Ameliorative effect of myo-inositol on red blood cell alterations in polycystic ovary syndrome: in vitro study. ( Ambrosini, G; Andrisani, A; Armanini, D; Bordin, L; Bosello Travain, V; Brunati, AM; Dessole, F; Donà, G; Marin, L; Ragazzi, E; Sabbadin, C; Tibaldi, E, 2018) |
| "Authors would like to demonstrate the beneficial effect of myo-inositol supplementation in a pregnant woman with insulin-dependent type 2 diabetes mellitus and polycystic ovary syndrome." | 3.85 | [The myo-inositol is beneficial in the therapy of pregnancy with insulin-dependent type 2 diabetes and polycystic ovary syndrome]. ( Kun, A; Tornóczky, J, 2017) |
| "The aim of our study was to investigate the effects of a combined treatment with alpha-lipoic acid (ALA) and myoinositol (MYO) on clinical, endocrine and metabolic features of women affected by polycystic ovary syndrome (PCOS)." | 3.85 | Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. ( Apa, R; De Cicco, S; Della Casa, S; Di Florio, C; Immediata, V; Lanzone, A; Policola, C; Romualdi, D; Scarinci, E; Tagliaferri, V; Tropea, A, 2017) |
| "To evaluate the effects of D-Chiro-Inositol in women affected by polycystic ovary syndrome (PCOS)." | 3.81 | Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. ( Barbaro, L; Laganà, AS; Pizzo, A, 2015) |
| "To evaluate the effects of the combination of d-chiro-inositol (DCI) and alpha lipoic acid on menses and metabolic disorders in women with polycystic ovary syndrome (PCOS)." | 3.81 | d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. ( Bartolo, M; Caruso, S; Cianci, A; Falduzzi, C; Fichera, M; Panella, M, 2015) |
| "In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d-chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ovary syndrome." | 3.81 | Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. ( Benvenga, S; Bevilacqua, A; Bizzarri, M; Carlomagno, G; Cavalli, P; Chiu, TT; D'Anna, R; Devroey, P; Di Renzo, GC; Facchinetti, F; Gerli, S; Hod, M; Kamenov, ZA; Lanzone, A; Oliva, MM; Soulage, C, 2015) |
| "Previous studies from our and other labs have shown that insulin resistance is associated with an inositol imbalance of excess myo-inositol and deficient chiro-inositol together with a deficiency of myo-inositol to chiro-inositol epimerase in vivo and in vitro." | 3.80 | Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. ( Heimark, D; Larner, J; McAllister, J, 2014) |
| "To investigate hormonal dynamics in a group of non-obese polycystic ovary syndrome (PCOS) patients under myo-inositol (MYO) administration." | 3.80 | Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. ( Campedelli, A; Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2014) |
| "The results of this study demonstrated a good efficacy of both treatments, although in the group treated with the combination of myo-inositol/monacolin K improvement in lipids and hyperandrogenism were significantly better." | 3.79 | [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women]. ( Cappelli, V; De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC, 2013) |
| "To evaluate retrospectively the prevalence of gestational diabetes (GD) in pregnancies obtained with myo-inositol administration in women with polycystic ovary syndrome." | 3.78 | Myo-inositol may prevent gestational diabetes in PCOS women. ( Corrado, F; D'Anna, R; Di Benedetto, A; Di Benedetto, V; Interdonato, ML; Raffone, E; Rizzo, P, 2012) |
| "Aim of the study was to evaluate the effects of 24 weeks administration of myo-inositol plus folic acid (Inofert ®) on clinical, endocrine and metabolic parameters of polycystic ovary syndrome (PCOS) patients." | 3.78 | [Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol]. ( D'Alessandro, P; De Trana, E; Mocciaro, R; Morelli, M; Venturella, R; Zullo, F, 2012) |
| "In an attempt to evaluate the role of inositol supplementation in insulin-resistant patients with polycystic ovary syndrome (PCOS), undergoing gonadotropin ovulation induction using the low-dose step-down regimen, we conducted a prospective longitudinal study comparing the stimulation characteristics of 15 patients treated with inositol, to a cohort, matched by age and body mass index (BMI), without inositol." | 3.77 | The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Orvieto, R, 2011) |
| "To evaluate the labeling accuracy of four myo-inositol products, designed for polycystic ovary syndrome (PCOS) treatment, available on the italian market and to perform a cost comparison based on myo-inositol content in milligrams for products analyzed." | 3.77 | Myo-inositol products in polycystic ovary syndrome (PCOS) treatment: quality, labeling accuracy, and cost comparison. ( De Michele, F; Molgora, M; Papaleo, E; Pellegrino, M; Quaranta, L, 2011) |
| " Increased clearance of inositols might reduce tissue availability of DCI and decrease the release of DCI-IPG mediator, which could contribute to insulin resistance and compensatory hyperinsulinemia in Greek women, as previously described in American women." | 3.74 | Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. ( Apridonidze, T; Baillargeon, JP; Diamanti-Kandarakis, E; Nestler, JE; Ostlund, RE, 2008) |
| "To assess this possibility in polycystic ovary syndrome (PCOS), we determined insulin sensitivity (Si by frequently sampled intravenous glucose tolerance test), plasma and urinary DCI and myo-inositol (MYO) levels (by gas chromatography/mass spectrometry), and the release of insulin and DCI-IPG during the oral glucose tolerance test (area under the curve [AUC]) in 23 women with PCOS and 26 normal women." | 3.73 | Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Diamanti-Kandarakis, E; Iuorno, MJ; Nestler, JE; Ostlund, RE, 2006) |
| "D-chiro-inositol (DCI) is a drug candidate for the treatment of type 2 diabetes and polycystic ovary syndrome, since it improves the efficiency with which the body uses insulin and also promotes ovulation." | 3.73 | Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. ( Ashida, H; Ikeuchi, M; Kinehara, M; Morinaga, T; Yamaguchi, M; Yoshida, K, 2006) |
| "To determine whether insulin stimulates human ovarian testosterone production in the polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system, thecal cells from polycystic ovary syndrome women were isolated and cultured." | 3.70 | Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. ( Brik, C; de Vargas, AF; Jakubowicz, DJ; Medina, F; Nestler, JE; Quintero, N, 1998) |
| "Myo-inositol is a natural polyol, the most abundant among the nine possible structural isomers available in living organisms." | 3.01 | Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. ( Angeloni, A; Bizzarri, M; Monti, N; Piombarolo, A; Verna, R, 2023) |
| "Polycystic Ovary Syndrome is the most prevalent hormonal disorder in females." | 3.01 | Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis. ( Adnan, A; Faheem, S; Fatima, K; Jamil, Z; Javaid, SS; Mohiuddin, N; Naeem, H; Ochani, S; Sajid, A, 2023) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 2.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| "Inositol treatments should be evaluated on the patients' specific conditions and needs, as long-term supplementation of high doses of DCI may cause detrimental effects on the ovarian functionality." | 2.82 | Inositols in the ovaries: activities and potential therapeutic applications. ( Alkatout, I; Bianco, B; Bizzarri, M; Forte, G; Gitas, G; Kamenov, ZA; Kaya, C; Laganà, AS; Terzic, M; Unfer, V, 2022) |
| "Pregnancy is similarly characterized by substantial and complex changes in glycemic and lipidomic regulation as part of maternal adaptation and is also associated with physiological alterations in inositol processing." | 2.82 | A review of the role of inositols in conditions of insulin dysregulation and in uncomplicated and pathological pregnancy. ( Chan, SY; Sharma, N; Watkins, OC; Yong, HEJ, 2022) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 2.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "Myo-inositol is a simple and safe treatment that is capable of restoring spontaneous ovarian activity and consequently fertility in most patients with PCOS." | 2.73 | Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. ( Baillargeon, JP; Brigante, C; Cino, I; De Santis, L; Ferrari, A; Fusi, F; Marelli, G; Papaleo, E; Redaelli, A; Unfer, V, 2007) |
| "These activities allow a treatment for polycystic ovary syndrome (PCOS) to be defined based on the combined administration of MI and DCI, where the best MI:DCI ratio is 40:1." | 2.66 | Inositols in Polycystic Ovary Syndrome: An Overview on the Advances. ( Dewailly, D; Diamanti-Kandarakis, E; Facchinetti, F; Kamenov, ZA; Laganà, AS; Nestler, JE; Soulage, CO; Unfer, V, 2020) |
| "Insulin resistance is becoming an increasingly studied target for therapy, most evidence stemming from the time-honored metformin use." | 2.66 | Current treatment for polycystic ovary syndrome: focus on adolescence. ( Catellani, C; Cirillo, F; Dauriz, M; Lazzeroni, P; Moghetti, P; Sartori, C; Street, ME, 2020) |
| "Metformin is a safe medication used in PCOS for 25 years that is currently recommended in select PCOS subpopulations, such as adolescents, women with metabolic disorders, and infertility infertile women undergoing ovarian hyperstimulation." | 2.61 | Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome. ( Banaszewska, B; Pawelczyk, L; Spaczynski, R, 2019) |
| " This analysis found no advantage in terms of PK for single 4 g dosing of myo-ins compared to 2 g twice a day, which allowed to get a 24-hour coverage, contrary to the singular dose." | 2.55 | Finding the best therapeutic approach for PCOS: the importance of inositol(s) bioavailability. ( Carlomagno, G; Circo, R; Logoteta, P; Orrù, B; Petousis, S, 2017) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 2.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| "Inositol is an organic compound of high biological importance that is widely distributed in nature." | 2.53 | Inositol and human reproduction. From cellular metabolism to clinical use. ( Czyzyk, A; Genazzani, AD; Meczekalski, B; Milewska, EM, 2016) |
| "Metformin was also associated with a significantly higher incidence of gastrointestinal disturbance, but no serious adverse effects were reported." | 2.45 | WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2009) |
| "Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear." | 1.56 | The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. ( Cabrera-Cruz, H; Oróstica, L; Plaza-Parrochia, F; Romero, C; Torres-Pinto, I; Vega, M, 2020) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 1.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "Polycystic ovary syndrome is characterized by irregular cycles, hyperandrogenism, polycystic ovary at ultrasound and insulin resistance." | 1.42 | The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. ( Cianci, A; Dondi, G; Grisendi, V; La Marca, A; Sighinolfi, G, 2015) |
| "Inositol is a physiological compound belonging to the sugar family." | 1.40 | Inositol: history of an effective therapy for Polycystic Ovary Syndrome. ( Bizzarri, M; Carlomagno, G, 2014) |
| "Inositol is a polyalcohol existing as nine different stereoisomers, two of which have been shown to be insulin mediators: myo-inositol (MI) and D-chiro-inositol (DCI)." | 1.37 | Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction. ( Galletta, M; Grasso, S; Roseff, SJ; Vaiarelli, A, 2011) |
| "Polycystic ovary syndrome is the most common cause of chronic anovulation infertility in women in fertile period." | 1.36 | [Effects of inositol on oocyte quality in patients affected with polycystic ovary syndrome]. ( Carbonaro, A; Ciotta, L; Gulino, F; Pagano, I; Palumbo, M; Stracquadanio, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.46) | 18.2507 |
| 2000's | 12 (5.85) | 29.6817 |
| 2010's | 123 (60.00) | 24.3611 |
| 2020's | 67 (32.68) | 2.80 |
| Authors | Studies |
|---|---|
| Rajasekaran, K | 1 |
| Malhotra, N | 1 |
| Mahey, R | 4 |
| Khadgawat, R | 4 |
| Kalaivani, M | 1 |
| Bezerra Espinola, MS | 2 |
| Laganà, AS | 19 |
| Bilotta, G | 1 |
| Gullo, G | 2 |
| Aragona, C | 4 |
| Unfer, V | 37 |
| Kachhawa, G | 3 |
| Senthil Kumar, KV | 1 |
| Kulshrestha, V | 1 |
| Bhatla, N | 2 |
| Dinicola, S | 5 |
| Facchinetti, F | 7 |
| Soulage, CO | 3 |
| Greene, ND | 1 |
| Bizzarri, M | 17 |
| Chan, SY | 2 |
| Bevilacqua, A | 8 |
| Pkhaladze, L | 2 |
| Benvenga, S | 4 |
| Stringaro, A | 1 |
| Barbaro, D | 1 |
| Appetecchia, M | 1 |
| Cantelmi, T | 2 |
| Cavalli, P | 2 |
| Chiu, TT | 4 |
| Copp, AJ | 2 |
| D'Anna, R | 4 |
| Dewailly, D | 4 |
| Di Lorenzo, C | 1 |
| Diamanti-Kandarakis, E | 4 |
| Hernández Marín, I | 2 |
| Hod, M | 2 |
| Kamenov, Z | 4 |
| Kandaraki, E | 1 |
| Monastra, G | 7 |
| Montanino Oliva, M | 3 |
| Nestler, JE | 12 |
| Nordio, M | 6 |
| Ozay, AC | 4 |
| Papalou, O | 1 |
| Porcaro, G | 2 |
| Prapas, N | 3 |
| Roseff, S | 3 |
| Vazquez-Levin, M | 2 |
| Vucenik, I | 2 |
| Wdowiak, A | 2 |
| Soldat-Stanković, V | 1 |
| Popović-Pejičić, S | 1 |
| Stanković, S | 1 |
| Prtina, A | 1 |
| Malešević, G | 1 |
| Bjekić-Macut, J | 1 |
| Livadas, S | 1 |
| Ognjanović, S | 1 |
| Mastorakos, G | 1 |
| Micić, D | 1 |
| Macut, D | 1 |
| Russo, M | 4 |
| Basciani, S | 3 |
| Khomasuridze, A | 1 |
| Mendoza, N | 3 |
| Losa, F | 1 |
| Palacios, S | 1 |
| Tabatabaie, M | 2 |
| Amiri, S | 1 |
| Golestan Jahromi, M | 1 |
| Sene, AA | 1 |
| Zandieh, Z | 2 |
| Mehdizadeh, M | 2 |
| Amjadi, F | 3 |
| Cianci, A | 4 |
| Vitale, SG | 1 |
| DiNicolantonio, JJ | 1 |
| H O'Keefe, J | 1 |
| Monti, N | 3 |
| Fedeli, V | 3 |
| Zhang, JQ | 1 |
| Xing, C | 3 |
| He, B | 3 |
| Forte, G | 5 |
| Kamenov, ZA | 4 |
| Bianco, B | 1 |
| Kaya, C | 1 |
| Gitas, G | 1 |
| Alkatout, I | 1 |
| Terzic, M | 1 |
| Jethaliya, H | 1 |
| Gajjar, N | 1 |
| Patel, V | 1 |
| Deshpande, S | 1 |
| Patel, R | 1 |
| Menichini, D | 1 |
| Ughetti, C | 1 |
| Monari, F | 1 |
| Di Vinci, PL | 1 |
| Neri, I | 1 |
| Cardinale, V | 1 |
| Lepore, E | 2 |
| Artale, S | 1 |
| Moslehi, N | 1 |
| Zeraattalab-Motlagh, S | 1 |
| Rahimi Sakak, F | 1 |
| Shab-Bidar, S | 1 |
| Tehrani, FR | 1 |
| Mirmiran, P | 1 |
| Hassan, S | 1 |
| Shah, M | 1 |
| Malik, MO | 1 |
| Ehtesham, E | 1 |
| Habib, SH | 1 |
| Rauf, B | 1 |
| Unanyan, A | 1 |
| Pivazyan, L | 1 |
| Krylova, E | 1 |
| Eskin, A | 1 |
| Zakaryan, A | 1 |
| Sarkisova, A | 1 |
| Ishchenko, A | 1 |
| Saei Ghare Naz, M | 2 |
| Jahanfar, S | 2 |
| Ramezani Tehrani, F | 2 |
| Scaglione, M | 1 |
| Leone, MC | 1 |
| Mugavero, M | 1 |
| Haghighi, M | 1 |
| Najafi, M | 1 |
| Artimani, T | 1 |
| Mohammadi, F | 1 |
| Mehdizadeh, R | 1 |
| Khmil, M | 1 |
| Khmil Doswald, A | 1 |
| Halnykina, S | 1 |
| Khmil, S | 1 |
| Greff, D | 1 |
| Juhász, AE | 1 |
| Váncsa, S | 1 |
| Váradi, A | 1 |
| Sipos, Z | 1 |
| Szinte, J | 1 |
| Park, S | 1 |
| Hegyi, P | 1 |
| Nyirády, P | 1 |
| Ács, N | 1 |
| Várbíró, S | 1 |
| Horváth, EM | 1 |
| Weston, E | 1 |
| Pangilinan, F | 1 |
| Eaton, S | 1 |
| Orford, M | 1 |
| Leung, KY | 1 |
| Mills, JL | 1 |
| Molloy, AM | 1 |
| Brody, LC | 1 |
| Greene, N | 1 |
| Catizone, A | 1 |
| Querqui, A | 1 |
| Guarnieri, G | 1 |
| Iervolino, M | 2 |
| Cavallone, S | 1 |
| Vianello, A | 1 |
| Piombarolo, A | 1 |
| Angeloni, A | 1 |
| Verna, R | 1 |
| Ramp, P | 1 |
| Mack, C | 1 |
| Wirtz, A | 1 |
| Bott, M | 1 |
| Fatima, K | 1 |
| Jamil, Z | 1 |
| Faheem, S | 1 |
| Adnan, A | 1 |
| Javaid, SS | 1 |
| Naeem, H | 1 |
| Mohiuddin, N | 1 |
| Sajid, A | 1 |
| Ochani, S | 1 |
| Nazirudeen, R | 1 |
| Sridhar, S | 1 |
| Priyanka, R | 1 |
| Sumathi, B | 1 |
| Natarajan, V | 1 |
| Subbiah, E | 1 |
| Raghavan, KS | 1 |
| Sangumani, J | 1 |
| Guarano, A | 1 |
| Capozzi, A | 2 |
| Cristodoro, M | 1 |
| Di Simone, N | 1 |
| Lello, S | 2 |
| Beresniak, A | 1 |
| Oliva, MM | 2 |
| Chiantera, V | 1 |
| Banaszewska, B | 1 |
| Pawelczyk, L | 1 |
| Spaczynski, R | 1 |
| Zuev, V | 1 |
| Lippa, A | 1 |
| Carra, MC | 1 |
| Lisi, F | 1 |
| Wojciechowska, A | 1 |
| Osowski, A | 1 |
| Jóźwik, M | 1 |
| Górecki, R | 1 |
| Rynkiewicz, A | 1 |
| Wojtkiewicz, J | 1 |
| Cabrera-Cruz, H | 1 |
| Oróstica, L | 1 |
| Plaza-Parrochia, F | 1 |
| Torres-Pinto, I | 1 |
| Romero, C | 1 |
| Vega, M | 1 |
| Zhang, Y | 1 |
| Li, C | 1 |
| Zhang, W | 1 |
| Zheng, X | 1 |
| Chen, X | 1 |
| Artini, PG | 4 |
| Obino, MER | 1 |
| Micelli, E | 1 |
| Malacarne, E | 2 |
| Vacca, C | 1 |
| Papini, F | 2 |
| Cela, V | 2 |
| Street, ME | 1 |
| Cirillo, F | 1 |
| Catellani, C | 1 |
| Dauriz, M | 1 |
| Lazzeroni, P | 1 |
| Sartori, C | 1 |
| Moghetti, P | 1 |
| Espinola, MSB | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Lei, W | 1 |
| Gao, Y | 1 |
| Hu, S | 1 |
| Liu, D | 1 |
| Chen, Q | 1 |
| Pericuesta, E | 1 |
| Laguna-Barraza, R | 1 |
| Ramos-Ibeas, P | 1 |
| Gutierrez-Arroyo, JL | 1 |
| Navarro, JA | 1 |
| Vera, K | 1 |
| Sanjuan, C | 1 |
| Baixeras, E | 1 |
| de Fonseca, FR | 1 |
| Gutierrez-Adan, A | 1 |
| Prabhakar, P | 1 |
| Gupta, M | 1 |
| Sharma, JB | 1 |
| Vanamail, P | 2 |
| Kumari, R | 1 |
| Genazzani, A | 2 |
| Yaylalı, A | 1 |
| Bakacak, M | 1 |
| Bakacak, Z | 1 |
| Gateva, A | 3 |
| Liu, X | 1 |
| Li, SP | 1 |
| Watkins, OC | 1 |
| Yong, HEJ | 1 |
| Sharma, N | 1 |
| Merviel, P | 1 |
| James, P | 1 |
| Bouée, S | 1 |
| Le Guillou, M | 1 |
| Rince, C | 1 |
| Nachtergaele, C | 1 |
| Kerlan, V | 1 |
| Gambioli, R | 2 |
| Almalki, WH | 1 |
| Lambiase, E | 1 |
| Unfer, VR | 1 |
| Azizi Kutenaei, M | 1 |
| Hosseini Teshnizi, S | 1 |
| Ghaemmaghami, P | 1 |
| Eini, F | 1 |
| Roozbeh, N | 1 |
| Harrath, AH | 3 |
| Alwasel, SH | 2 |
| Picconi, O | 1 |
| Costabile, L | 1 |
| Zhang, J | 2 |
| Zhao, H | 2 |
| Buzzaccarini, G | 1 |
| Dragotto, J | 2 |
| Lucarelli, M | 1 |
| Di Emidio, G | 1 |
| Tatone, C | 1 |
| Logoteta, P | 2 |
| Tomatis, V | 1 |
| Genazzani, AD | 10 |
| Kun, A | 1 |
| Tornóczky, J | 1 |
| De Cicco, S | 2 |
| Immediata, V | 2 |
| Romualdi, D | 2 |
| Policola, C | 1 |
| Tropea, A | 1 |
| Di Florio, C | 2 |
| Tagliaferri, V | 2 |
| Scarinci, E | 1 |
| Della Casa, S | 1 |
| Lanzone, A | 3 |
| Apa, R | 1 |
| Jamilian, M | 2 |
| Farhat, P | 1 |
| Foroozanfard, F | 3 |
| Afshar Ebrahimi, F | 3 |
| Aghadavod, E | 2 |
| Bahmani, F | 2 |
| Badehnoosh, B | 1 |
| Jamilian, H | 2 |
| Asemi, Z | 3 |
| LE, TN | 1 |
| Wickham, EP | 1 |
| Pundir, J | 5 |
| Psaroudakis, D | 3 |
| Savnur, P | 3 |
| Bhide, P | 4 |
| Sabatini, L | 4 |
| Teede, H | 4 |
| Coomarasamy, A | 4 |
| Thangaratinam, S | 4 |
| Tewari, S | 1 |
| Narula, SC | 1 |
| Singhal, SR | 1 |
| Sharma, RK | 1 |
| Nas, K | 1 |
| Tűű, L | 1 |
| Rolland, AL | 1 |
| Peigné, M | 1 |
| Plouvier, P | 1 |
| Dumont, A | 1 |
| Catteau-Jonard, S | 1 |
| Orrù, B | 3 |
| Circo, R | 1 |
| Petousis, S | 1 |
| Carlomagno, G | 10 |
| Pérez, L | 1 |
| Simoncini, T | 5 |
| Scioscia, M | 1 |
| Fascilla, F | 1 |
| Bettocchi, S | 1 |
| Morgante, G | 6 |
| Massaro, MG | 3 |
| Di Sabatino, A | 5 |
| Cappelli, V | 6 |
| De Leo, V | 8 |
| Andrisani, A | 1 |
| Donà, G | 2 |
| Sabbadin, C | 2 |
| Tibaldi, E | 1 |
| Dessole, F | 1 |
| Bosello Travain, V | 1 |
| Marin, L | 1 |
| Brunati, AM | 1 |
| Ambrosini, G | 2 |
| Armanini, D | 2 |
| Ragazzi, E | 2 |
| Bordin, L | 2 |
| Zeng, L | 1 |
| Yang, K | 1 |
| Morley, LC | 1 |
| Tang, T | 5 |
| Yasmin, E | 5 |
| Norman, RJ | 6 |
| Balen, AH | 5 |
| Hibberd, R | 1 |
| Raine-Fenning, N | 1 |
| Thornton, J | 1 |
| Ravanos, K | 1 |
| Pavlidou, T | 1 |
| Goudakou, M | 1 |
| Stracquadanio, M | 4 |
| Ciotta, L | 4 |
| Palumbo, MA | 1 |
| Regidor, PA | 1 |
| Schindler, AE | 1 |
| Lesoine, B | 1 |
| Druckman, R | 1 |
| Buonomo, G | 1 |
| Calcagno, M | 1 |
| Levin, G | 1 |
| Rottenstreich, A | 1 |
| Vitagliano, A | 3 |
| Noventa, M | 3 |
| Garzon, S | 1 |
| Casarin, J | 1 |
| Franchi, M | 1 |
| Ghezzi, F | 1 |
| Ortiz-Flores, AE | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 1 |
| Giuliani, A | 1 |
| Cutler, DA | 1 |
| Shaw, AK | 1 |
| Pride, SM | 1 |
| Bedaiwy, MA | 1 |
| Cheung, AP | 1 |
| Showell, MG | 1 |
| Mackenzie-Proctor, R | 1 |
| Jordan, V | 1 |
| Hodgson, R | 1 |
| Farquhar, C | 1 |
| Shokrpour, M | 1 |
| Vahedpoor, Z | 1 |
| Ghaderi, A | 1 |
| Charles, D | 1 |
| Hiam, D | 1 |
| Jitpiriyaroj, S | 1 |
| Moran, L | 1 |
| Fruzzetti, F | 3 |
| Canu, A | 1 |
| Grandi, G | 1 |
| Agrawal, A | 1 |
| Kriplani, A | 1 |
| Emekçi Özay, Ö | 2 |
| Okyay, RE | 2 |
| Gülekli, B | 2 |
| Quinlivan, JA | 1 |
| McGowan, L | 1 |
| Januszewski, M | 1 |
| Issat, T | 1 |
| Jakimiuk, AA | 1 |
| Santor-Zaczynska, M | 1 |
| Jakimiuk, AJ | 2 |
| Pourghasem, S | 1 |
| Bazarganipour, F | 1 |
| Taghavi, SA | 1 |
| Kutenaee, MA | 1 |
| Diaz-Ropero, MP | 1 |
| Aragon, M | 1 |
| Maldonado, V | 1 |
| Llaneza, P | 1 |
| Lorente, J | 1 |
| Mendoza-Tesarik, R | 1 |
| Maldonado-Lobon, J | 1 |
| Olivares, M | 1 |
| Fonolla, J | 1 |
| Troisi, J | 1 |
| Cinque, C | 1 |
| Giugliano, L | 1 |
| Symes, S | 1 |
| Richards, S | 1 |
| Adair, D | 1 |
| Cavallo, P | 1 |
| Sarno, L | 1 |
| Scala, G | 1 |
| Caiazza, M | 1 |
| Guida, M | 1 |
| Le Donne, M | 2 |
| Metro, D | 1 |
| Alibrandi, A | 2 |
| Papa, M | 1 |
| Akbari Sene, A | 1 |
| Tabatabaie, A | 1 |
| Nikniaz, H | 1 |
| Alizadeh, A | 1 |
| Sheibani, K | 1 |
| Mortezapour Alisaraie, M | 1 |
| Ashrafi, M | 1 |
| Gudi, A | 1 |
| Shah, A | 1 |
| Homburg, R | 1 |
| Acharya, G | 1 |
| Camajani, E | 1 |
| Prati, A | 4 |
| Marchini, F | 1 |
| Petrillo, T | 1 |
| Napolitano, A | 1 |
| Fidecicchi, T | 1 |
| Palla, G | 1 |
| Gambacciani, M | 1 |
| Advani, K | 1 |
| Batra, M | 1 |
| Tajpuriya, S | 1 |
| Gupta, R | 1 |
| Saraswat, A | 1 |
| Nagar, HD | 1 |
| Makwana, L | 1 |
| Kshirsagar, S | 1 |
| Kaul, P | 1 |
| Ghosh, AK | 1 |
| Pradhan, S | 1 |
| Mehta, A | 1 |
| Jaiswal, A | 1 |
| Nakhate, KT | 1 |
| Kamdi, S | 1 |
| Musacchio, MC | 4 |
| Minozzi, M | 2 |
| Pajalich, R | 1 |
| Colazingari, S | 1 |
| Treglia, M | 1 |
| Najjar, R | 1 |
| Croze, ML | 1 |
| Orvieto, R | 2 |
| Heimark, D | 1 |
| McAllister, J | 1 |
| Larner, J | 1 |
| Pizzo, A | 3 |
| Barbaro, L | 2 |
| Szamatowicz, J | 1 |
| Santagni, S | 3 |
| Rattighieri, E | 3 |
| Chierchia, E | 3 |
| Despini, G | 2 |
| Marini, G | 2 |
| Ricchieri, F | 3 |
| Campedelli, A | 2 |
| Křepelka, P | 1 |
| Piomboni, P | 1 |
| Focarelli, R | 1 |
| Capaldo, A | 1 |
| Stendardi, A | 1 |
| La Marca, A | 2 |
| Luddi, A | 1 |
| Kolarov, G | 1 |
| Grisendi, V | 1 |
| Dondi, G | 1 |
| Sighinolfi, G | 1 |
| Tosti, C | 1 |
| Cianci, EA | 1 |
| Gizzo, S | 2 |
| Formuso, C | 1 |
| Quaranta, M | 1 |
| Vitek, W | 1 |
| Alur, S | 1 |
| Hoeger, KM | 1 |
| Panella, M | 1 |
| Fichera, M | 1 |
| Falduzzi, C | 1 |
| Bartolo, M | 1 |
| Caruso, S | 1 |
| Soulage, C | 1 |
| Di Renzo, GC | 1 |
| Gerli, S | 1 |
| Devroey, P | 1 |
| Pacchiarotti, A | 2 |
| Antonini, G | 1 |
| Alviggi, C | 1 |
| Cariati, F | 1 |
| Conforti, A | 1 |
| De Rosa, P | 1 |
| Vallone, R | 1 |
| Strina, I | 1 |
| Pivonello, R | 1 |
| De Placido, G | 1 |
| Paul, C | 1 |
| Maniglio, P | 1 |
| Triolo, O | 1 |
| Brady, DM | 1 |
| Cucina, A | 1 |
| Muscogiuri, G | 1 |
| Palomba, S | 1 |
| Orio, F | 1 |
| Milewska, EM | 1 |
| Czyzyk, A | 1 |
| Meczekalski, B | 1 |
| Perini, D | 1 |
| Bucci, F | 1 |
| Gadducci, A | 1 |
| Legro, RS | 1 |
| Guido, M | 1 |
| Çağlıyan, E | 1 |
| Zacchè, MM | 1 |
| Caputo, L | 1 |
| Filippis, S | 1 |
| Zacchè, G | 1 |
| Dindelli, M | 1 |
| Ferrari, A | 2 |
| Lord, JM | 5 |
| Papaleo, E | 5 |
| Baillargeon, JP | 6 |
| Iuorno, MJ | 3 |
| Apridonidze, T | 3 |
| Raffone, E | 4 |
| Rizzo, P | 4 |
| Benedetto, V | 1 |
| Pechlivanov, B | 1 |
| Pagano, I | 2 |
| Carbonaro, A | 2 |
| Palumbo, M | 2 |
| Gulino, F | 2 |
| Galazis, N | 1 |
| Galazi, M | 1 |
| Atiomo, W | 1 |
| Costantino, D | 1 |
| Guaraldi, C | 1 |
| Molgora, M | 1 |
| Quaranta, L | 1 |
| Pellegrino, M | 1 |
| De Michele, F | 1 |
| Cittadini, E | 1 |
| Di Benedetto, V | 1 |
| Interdonato, ML | 1 |
| Corrado, F | 1 |
| Di Benedetto, A | 1 |
| Galletta, M | 1 |
| Grasso, S | 1 |
| Vaiarelli, A | 1 |
| Roseff, SJ | 1 |
| Fiore, C | 1 |
| Bragadin, M | 1 |
| Giorgino, FL | 1 |
| Clari, G | 1 |
| Dante, G | 1 |
| Giarrusso, R | 1 |
| Lo Monaco, I | 1 |
| Muraca, U | 1 |
| Kedikova, S | 1 |
| Sirakov, M | 1 |
| Boyadzhieva, M | 1 |
| Venturella, R | 1 |
| Mocciaro, R | 1 |
| De Trana, E | 1 |
| D'Alessandro, P | 1 |
| Morelli, M | 1 |
| Zullo, F | 1 |
| Proietti, E | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Ruggiero, M | 1 |
| Flight, IH | 1 |
| Ostlund, RE | 2 |
| Yoshida, K | 1 |
| Yamaguchi, M | 1 |
| Morinaga, T | 1 |
| Ikeuchi, M | 1 |
| Kinehara, M | 1 |
| Ashida, H | 1 |
| De Santis, L | 2 |
| Fusi, F | 2 |
| Brigante, C | 1 |
| Marelli, G | 1 |
| Cino, I | 1 |
| Redaelli, A | 1 |
| Lanzoni, C | 1 |
| Jasonni, VM | 1 |
| Occhi, F | 1 |
| Jakubowicz, DJ | 3 |
| de Vargas, AF | 1 |
| Brik, C | 1 |
| Quintero, N | 1 |
| Medina, F | 1 |
| Reamer, P | 1 |
| Gunn, RD | 1 |
| Allan, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Inositols on Insulin Resistance in Children With Obesity (ONIRICO Trial)[NCT05701813] | 56 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | |||
| Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome[NCT04867252] | Phase 2 | 88 participants (Actual) | Interventional | 2021-05-03 | Completed | ||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Altered Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid of Women Undergoing in Vitro Fertilization Has Detrimental Effects on Oocyte and Embryo Quality[NCT03055442] | 34 participants (Actual) | Observational | 2016-10-31 | Completed | |||
| Improved Effects of Myo-inositol in Association With Alpha-lactalbumin in PCOS Women[NCT03422289] | 37 participants (Actual) | Interventional | 2016-11-02 | Completed | |||
| Graceful Lifestyle Changes Intervention Study for Women With PCOS and Infertility[NCT02630485] | 240 participants (Anticipated) | Interventional | 2015-12-31 | Not yet recruiting | |||
| Effects of a Combined Treatment With Myo-inositol, D-chiro-inositol and Glucomannan in Women With PCOS[NCT03608813] | 120 participants (Actual) | Observational | 2016-09-10 | Completed | |||
| Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial[NCT04273256] | Phase 2/Phase 3 | 226 participants (Anticipated) | Interventional | 2020-02-11 | Recruiting | ||
| Effect of Myoinositol on Serum Asprosin Levels in Pregnant Women[NCT05943158] | 40 participants (Actual) | Interventional | 2021-06-01 | Completed | |||
| Different Effects of Inositol Stereoisomers on Insulin Sensitivity in Women With Gestational Diabetes[NCT02097069] | 80 participants (Anticipated) | Interventional | 2014-04-30 | Not yet recruiting | |||
| Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity[NCT03283813] | Phase 4 | 60 participants (Anticipated) | Interventional | 2018-02-05 | Recruiting | ||
| Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study[NCT03875755] | 1,080 participants (Anticipated) | Interventional | 2020-03-04 | Recruiting | |||
| Evaluation Concerning the Influence of Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment[NCT02385396] | Phase 2 | 217 participants (Actual) | Interventional | Completed | |||
| Treatment of Functional Ovarian Cyst Randomised Clinical Trial[NCT05244811] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-02-20 | Not yet recruiting | ||
| Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation[NCT03352869] | Phase 4 | 183 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women[NCT01290432] | 15 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients.[NCT01246310] | 24 participants (Actual) | Interventional | 2010-11-30 | Terminated (stopped due to The number of patients enrolled was insufficient to match the calculated sample size and to carry out statistical analyses) | |||
| Improving Oocyte Retrieval Using a Combined Therapy of Recombinant Follicle Stimulating Hormone (rFSH) and Inositol and Melatonin[NCT01267604] | Phase 4 | 0 participants (Actual) | Interventional | 2010-12-31 | Withdrawn | ||
| A Prospective, Randomized, Double Blind, Study on the Clinical Efficacy Myo-inositol Versus D-chiro-inositol in Women Undergoing in Vitro Fertilization Embryo Transfer.[NCT01338844] | Phase 4 | 0 participants | Interventional | Completed | |||
| [NCT01511835] | Phase 4 | 0 participants | Interventional | Recruiting | |||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| [NCT01514942] | Phase 4 | 0 participants | Interventional | Completed | |||
| [NCT01511822] | Phase 4 | 0 participants | Interventional | Completed | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [NCT01626443] | Phase 4 | 46 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Effects of Myo-inositol Plus Melatonin in Perimenopausal Women[NCT01325389] | 0 participants | Interventional | Recruiting | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
72 reviews available for inositol and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Inositols: From Established Knowledge to Novel Approaches.
Topics: Diabetes, Gestational; Female; Humans; Inositol; Molecular Structure; Polycystic Ovary Syndrome; Pre | 2021 |
Strategy to improve the female fertility in the general gynecologist's office: use of a nutritional supplement based on myo-inositol/D-chiro-inositol and antioxidants.
Topics: Antioxidants; Female; Fertility; Humans; Inositol; Polycystic Ovary Syndrome; Pregnancy; Pregnancy R | 2022 |
D-Chiro-inositol and PCOS: between myth and reality. The never-ending story.
Topics: Dietary Supplements; Female; Humans; Inositol; Polycystic Ovary Syndrome | 2022 |
Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials.
Topics: Female; Glycolipids; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic Ovary Syndrome; Ra | 2022 |
Inositols in the ovaries: activities and potential therapeutic applications.
Topics: Female; Genital Diseases, Female; Humans; Inositol; Insulin; Polycystic Ovary Syndrome | 2022 |
Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.
Topics: Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2022 |
Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature.
Topics: Dietary Supplements; Female; Glucose; Humans; Hyperandrogenism; Inositol; Polycystic Ovary Syndrome; | 2022 |
Positive Effects of α-Lactalbumin in the Management of Symptoms of Polycystic Ovary Syndrome.
Topics: Dysbiosis; Female; Humans; Inositol; Insulin Resistance; Lactalbumin; Polycystic Ovary Syndrome; Pre | 2022 |
Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Live Birth; Metformin; Polycystic Ovary Syndrome; Pre | 2022 |
An overview on effects of micronutrients and macronutrients interventions in management of polycystic ovary syndrome.
Topics: Diet; Female; Humans; Inositol; Micronutrients; Nutrients; Polycystic Ovary Syndrome | 2022 |
An overview on effects of micronutrients and macronutrients interventions in management of polycystic ovary syndrome.
Topics: Diet; Female; Humans; Inositol; Micronutrients; Nutrients; Polycystic Ovary Syndrome | 2022 |
An overview on effects of micronutrients and macronutrients interventions in management of polycystic ovary syndrome.
Topics: Diet; Female; Humans; Inositol; Micronutrients; Nutrients; Polycystic Ovary Syndrome | 2022 |
An overview on effects of micronutrients and macronutrients interventions in management of polycystic ovary syndrome.
Topics: Diet; Female; Humans; Inositol; Micronutrients; Nutrients; Polycystic Ovary Syndrome | 2022 |
Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Insulins; Metformin; Polycystic Ovary Syndrome; Rando | 2023 |
The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner's Results.
Topics: Androgens; Aromatase; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Ino | 2023 |
The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol.
Topics: Asthma; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2023 |
Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review.
Topics: Aromatase; Female; Glucose; Humans; Inositol; Inositol Phosphates; Polycystic Ovary Syndrome | 2023 |
Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis.
Topics: Blood Glucose; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inositol; Metformi | 2023 |
Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin; Insulin Resistance; Metf | 2023 |
Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome.
Topics: Antioxidants; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; I | 2019 |
Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
Topics: Female; Humans; Inositol; Metabolome; Polycystic Ovary Syndrome; Treatment Outcome; Vitamin B Comple | 2019 |
Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
Topics: Animals; Female; Humans; Inositol; Polycystic Ovary Syndrome; Vitamin B Complex | 2020 |
Current treatment for polycystic ovary syndrome: focus on adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Female; Gene-Environment Interaction; Humans; Hypoglycem | 2020 |
Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART).
Topics: Female; Fertilization in Vitro; Humans; Inositol; Male; Polycystic Ovary Syndrome; Reproductive Tech | 2020 |
Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS.
Topics: Androgens; Aromatase; Estrogens; Female; Gene Expression Regulation; Granulosa Cells; Humans; Inosit | 2020 |
Inositols in PCOS.
Topics: Animals; Female; Humans; Inositol; Ovulation; Polycystic Ovary Syndrome | 2020 |
A review of the role of inositols in conditions of insulin dysregulation and in uncomplicated and pathological pregnancy.
Topics: Diabetes, Gestational; Female; Humans; Inositol; Insulin; Placenta; Polycystic Ovary Syndrome; Pregn | 2022 |
Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies.
Topics: Female; Fertilization in Vitro; Humans; Inositol; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Ra | 2021 |
The use of D-chiro-Inositol in clinical practice.
Topics: Aromatase; Down-Regulation; Female; Humans; Inositol; Insulin; Insulin Resistance; Male; Polycystic | 2021 |
A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome.
Topics: Adipose Tissue; Androgens; Animals; Anovulation; Female; Humans; Inositol; Polycystic Ovary Syndrome | 2021 |
Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women.
Topics: Female; Humans; Inositol; Polycystic Ovary Syndrome | 2021 |
The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic Ovary S | 2021 |
The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis.
Topics: Dietary Supplements; Female; Humans; Inositol; Polycystic Ovary Syndrome; Ubiquinone; Vitamin D; Vit | 2021 |
Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.
Topics: Ascorbic Acid; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Female; Flavanones; Flavono | 2021 |
An innovative approach to polycystic ovary syndrome.
Topics: Female; Humans; Infertility, Female; Inositol; Insulin; Male; Polycystic Ovary Syndrome | 2022 |
Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Topics: Berberine; Clinical Decision-Making; Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin | 2021 |
Insulin sensitizers in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Age Factors; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; | 2017 |
Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Female; Humans; Infertility; Inositol; Polycystic Ovary Syndrome; Randomized Controlled | 2018 |
Finding the best therapeutic approach for PCOS: the importance of inositol(s) bioavailability.
Topics: Area Under Curve; Biological Availability; Female; Humans; Inositol; Polycystic Ovary Syndrome; Ster | 2017 |
Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.
Topics: Female; Humans; Inositol; Oocytes; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; | 2017 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Estradiol; Female; Humans; Inositol; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Tri | 2018 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
Topics: Diabetes, Gestational; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome; Preg | 2018 |
Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.
Topics: Disease Management; Female; Fertilization in Vitro; Folic Acid; Glucose; Humans; Infertility, Female | 2018 |
Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials.
Topics: Dietary Supplements; Female; Fertilization in Vitro; Gonadotropins; Humans; Inositol; Ovulation Indu | 2018 |
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Topics: Female; Fertility; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2018 |
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
Topics: Animals; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Inositol; Insulin; Insulin Resistan | 2018 |
Inositol for subfertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Birth Rate; Clomiphene; Combined Modality Therapy; Fema | 2018 |
Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Off-Label Use; Polycystic Ovary Syndrome; | 2019 |
The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis.
Topics: Anti-Mullerian Hormone; Female; Fertilization in Vitro; Humans; Inositol; Ovarian Follicle; Ovarian | 2019 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
[The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders].
Topics: Blood Glucose; Female; Folic Acid; Follicular Phase; Humans; Inositol; Ovary; Polycystic Ovary Syndr | 2014 |
Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Topics: Animals; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Inositol; Insulin Resis | 2014 |
The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Topics: Androgens; Animals; Drug Therapy, Combination; Female; Humans; Inositol; Insulin Resistance; Oocytes | 2014 |
[Myo-inositol in the treatment of polycystic ovary syndrome].
Topics: Female; Humans; Inositol; Polycystic Ovary Syndrome; Vitamin B Complex | 2014 |
Off-label drug use in the treatment of polycystic ovary syndrome.
Topics: Clomiphene; Contraceptives, Oral; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Off-Labe | 2015 |
Reflections on inositol(s) for PCOS therapy: steps toward success.
Topics: Female; Humans; Inositol; Polycystic Ovary Syndrome | 2015 |
Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin Resistance; Metabolic Syndrome; Polycys | 2016 |
Physiological role and clinical utility of inositols in polycystic ovary syndrome.
Topics: Female; Humans; Hyperinsulinism; Inositol; Insulin Resistance; Polycystic Ovary Syndrome; Stereoisom | 2016 |
Current Insights Into Inositol Isoforms, Mediterranean and Ketogenic Diets for Polycystic Ovary Syndrome: From Bench to Bedside.
Topics: Diet, Ketogenic; Diet, Mediterranean; Female; Humans; Inositol; Polycystic Ovary Syndrome; Protein I | 2016 |
Inositol and human reproduction. From cellular metabolism to clinical use.
Topics: Female; Humans; Inositol; Insulin Resistance; Ovulation; Polycystic Ovary Syndrome; Reproductive Tec | 2016 |
Inositol as putative integrative treatment for PCOS.
Topics: Female; Humans; Hyperandrogenism; Hyperinsulinism; Inositol; Inositol Phosphates; Insulin; Insulin R | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
Topics: Female; Humans; Inositol; Polycystic Ovary Syndrome; Vitamin B Complex | 2017 |
WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Inducti | 2009 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Live Bir | 2010 |
[Myo-inositol in the treatment of hormonal, metabolic and reproductive features of polycystic ovary syndrome (review of the literature].
Topics: Female; Humans; Inositol; Polycystic Ovary Syndrome | 2010 |
D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Inositol; Insulin Resistance; Ovulation; Polycystic Ovary Syndrome | 2011 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin | 2012 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction | 2003 |
Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
Topics: Androgens; Female; Humans; Inositol; Inositol Phosphates; Insulin; Insulin Resistance; Oligosacchari | 2000 |
49 trials available for inositol and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Myoinositol
Topics: Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Inositol; Metformin; Ovarian | 2022 |
Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Topics: Female; Humans; Inositol; Insulin Resistance; Luteinizing Hormone; Menstrual Cycle; Polycystic Ovary | 2022 |
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
Topics: Adiponectin; Adult; Blood Glucose; Body Composition; Body Mass Index; Female; Gonadal Steroid Hormon | 2022 |
Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
Topics: Adolescent; Age Factors; Androstenes; Body Mass Index; Contraceptives, Oral; Ethinyl Estradiol; Fema | 2021 |
Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.
Topics: Adiponectin; Adult; Female; Follicle Stimulating Hormone; Humans; Inositol; Insulin; Luteinizing Hor | 2023 |
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ov | 2023 |
Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol | 2021 |
A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients.
Topics: Adolescent; Adult; Female; Humans; Inositol; Italy; Lactalbumin; Mexico; Overweight; Polycystic Ovar | 2021 |
Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial.
Topics: Adolescent; Adult; C-Reactive Protein; Cytokines; Female; Gene Expression; Humans; Inositol; Interle | 2017 |
Effect of Non-Surgical Periodontal Therapy Along With Myo-Inositol on High-Sensitivity C-Reactive Protein and Insulin Resistance in Women With Polycystic Ovary Syndrome and Chronic Periodontitis: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Anthropometry; C-Reactive Protein; Chronic Periodontitis; Demography; Dental Scal | 2017 |
Could myo-inositol soft gel capsules outperform clomiphene in inducing ovulation? Results of a pilot study.
Topics: Adolescent; Adult; Capsules; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female | 2017 |
Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anxiety; Biomarkers; Depression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; In | 2018 |
Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality?
Topics: Adult; Blastocyst; Embryo Transfer; Female; Fertilization in Vitro; Follicular Fluid; Humans; Inosit | 2017 |
Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women.
Topics: Adult; Dietary Supplements; Drug Combinations; Drug Resistance; Female; Folic Acid; Humans; Inositol | 2018 |
A randomized controlled trial comparing lifestyle intervention to letrozole for ovulation in women with polycystic ovary syndrome: a study protocol.
Topics: Administration, Oral; Adolescent; Adult; Diet, Healthy; Exercise; Female; Fertility Agents, Female; | 2018 |
Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial.
Topics: Adolescent; Adult; Blood Glucose; Female; Gene Expression; Humans; Hypoglycemic Agents; Inositol; In | 2019 |
Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial.
Topics: Adult; Birth Rate; Drug Synergism; Drug Therapy, Combination; Female; Fertility Agents, Female; Fert | 2019 |
The effect of myoinositol on ovarian blood flows in women with polycystic ovary syndrome.
Topics: Adult; Ethinyl Estradiol; Female; Humans; Inositol; Ovary; Polycystic Ovary Syndrome; Regional Blood | 2019 |
The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole.
Topics: Adult; Female; Folic Acid; Humans; Infertility, Female; Inositol; Letrozole; Metformin; Ovulation In | 2019 |
Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
Topics: Adolescent; Adult; Birth Rate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Compoundi | 2019 |
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study.
Topics: Adolescent; Adult; Body Mass Index; Case-Control Studies; Drug Therapy, Combination; Female; Humans; | 2019 |
The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial.
Topics: Adult; Double-Blind Method; Female; Fertilization in Vitro; Folic Acid; Humans; Infertility, Female; | 2019 |
The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Topics: Adolescent; Adult; Animals; Drug Administration Schedule; Drug Combinations; Estradiol; Female; Foll | 2019 |
The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
Topics: Adult; Biomarkers; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Inositol; Oocy | 2013 |
[Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Topics: Adult; Antioxidants; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Electron Transport; | 2013 |
Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Topics: Adolescent; Adult; Amenorrhea; Dietary Supplements; Double-Blind Method; Female; Folic Acid; Follicl | 2014 |
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Family Health; Female; Gonadotropin-Releasing Hormone; | 2014 |
Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Infant, Newborn; Infertility, Female; I | 2015 |
[Combination inositol and glucomannan in PCOS patients].
Topics: Adult; Blood Glucose; Drug Therapy, Combination; Female; Humans; Inositol; Insulin; Insulin Resistan | 2014 |
Myo-inositol vs. D-chiro inositol in PCOS treatment.
Topics: Acne Vulgaris; Adult; Double-Blind Method; Female; Hirsutism; Humans; Inositol; Insulin Resistance; | 2015 |
Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Topics: Adult; Antioxidants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fem | 2015 |
Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome.
Topics: Adult; Antioxidants; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Embryo Tra | 2016 |
Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Metformin; Out | 2017 |
Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study.
Topics: Adult; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Obesity; Outcom | 2017 |
Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial.
Topics: Adult; Female; Fertility Agents, Female; Follicle Stimulating Hormone; Humans; Inositol; Inseminatio | 2017 |
Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Cross-Sectional Studies; Diazoxide; Female; Glucose Clamp T | 2010 |
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women.
Topics: Adult; Anovulation; Dietary Supplements; Drug Therapy, Combination; Female; Fertility Agents, Female | 2010 |
The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Cholesterol; Cholesterol, LDL; Contraceptives, Oral, Combined; Female; Human | 2011 |
Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Female; Humans; Inositol; Oocytes; Polycystic Ovary Syndrome; Prospective Studies; Sperm Inje | 2011 |
Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial.
Topics: Adult; Dietary Supplements; Female; Humans; Inositol; Oocytes; Ovulation Induction; Polycystic Ovary | 2011 |
Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Down-Regulation; Drug Administration Schedule; Erythrocyte Count; Erythrocytes | 2012 |
[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
Topics: Adolescent; Adult; Body Composition; Combined Modality Therapy; Drug Therapy, Combination; Female; H | 2012 |
Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Female; Folic Acid; Follicle Stimulating Hormone; Gluco | 2012 |
The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Topics: Adolescent; Adult; Analysis of Variance; Biomarkers; Drug Combinations; Female; Humans; Inositol; Me | 2012 |
Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Drug Therapy, Combination; Estradiol; Female; Folic Acid; | 2013 |
Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
Topics: Adult; Drug Therapy, Combination; Female; Folic Acid; Humans; Infertility, Female; Inositol; Live Bi | 2007 |
Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Body Weight; Estradiol; Female; Folic Acid; Follicle Stimulating Hor | 2008 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Humans; Inositol; Male; Oocytes; Polycystic Ovary | 2009 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Inositol; | 1999 |
84 other studies available for inositol and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
D-chiro-inositol Induces Ovulation in Non-Polycystic Ovary Syndrome (PCOS), Non-Insulin-Resistant Young Women, Likely by Modulating Aromatase Expression: A Report of 2 Cases.
Topics: Aromatase; Female; Humans; Inositol; Ovulation; Ovulation Induction; Polycystic Ovary Syndrome | 2021 |
The effect of Myo-Inositol supplement on molecular regulation of folliculogenesis, steroidogenesis, and assisted reproductive technique outcomes in patients with polycystic ovarian syndrome.
Topics: Adult; Cumulus Cells; Dietary Supplements; Female; Fertilization in Vitro; Folic Acid; Gonadal Stero | 2022 |
Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes.
Topics: Diabetes, Gestational; Female; Humans; Inositol; Insulin; Insulin Resistance; Polycystic Ovary Syndr | 2022 |
Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?
Topics: Female; Humans; Inositol; Insulin; Insulin Resistance; Polycystic Ovary Syndrome; Thioctic Acid | 2022 |
D-Chiro-inositol in PCOS: the myths and what we know about the reality.
Topics: Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2022 |
Effects of nutrition on metabolic and endocrine outcomes in women with polycystic ovary syndrome: an umbrella review of meta-analyses of randomized controlled trials.
Topics: Blood Glucose; Curcumin; Female; Fish Oils; Humans; Inositol; Insulin; Insulin Resistance; Polycysti | 2023 |
The multiple roles of inositol in fertility and newborn outcomes.
Topics: Female; Fertility; Humans; Infant, Newborn; Inositol; Polycystic Ovary Syndrome | 2022 |
Effects of myo-inositol plus folic acid on ovarian morphology and oocyte quality in PCOS mouse model.
Topics: Adenosine Triphosphate; Animals; Dehydroepiandrosterone; Female; Folic Acid; Glutathione; Humans; In | 2023 |
Hormonal profile in women with infertility against the background of polycystic ovary syndrome depending on the type of pre-pregnancy pre-treatment.
Topics: Cholecalciferol; Female; Humans; Infertility, Female; Inositol; Ovulation Induction; Polycystic Ovar | 2022 |
Investigating Genetic Determinants of Plasma Inositol Status in Adult Humans.
Topics: Diet; Female; Genome-Wide Association Study; Glucose; Humans; Inositol; Male; Membrane Proteins; Mem | 2022 |
A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?
Topics: Female; Humans; Inositol; Phenotype; Polycystic Ovary Syndrome | 2023 |
Alternative routes for production of the drug candidate d-chiro-inositol with Corynebacterium glutamicum using endogenous or promiscuous plant enzymes.
Topics: Corynebacterium glutamicum; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Inositol; Oxidoreduc | 2023 |
A Markov-model simulation of IVF programs for PCOS patients indicates that coupling myo-Inositol with rFSH is cost-effective for the Italian Health System.
Topics: Cost-Benefit Analysis; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Inosito | 2023 |
Efficacy of the synergic action of myoinositol, tyrosine, selenium and chromium in women with PCOS.
Topics: Body Weight; Chromium; Dose-Response Relationship, Drug; Female; Humans; Inositol; Polycystic Ovary | 2019 |
D-Chiro-Inositol's action as aromatase inhibitor: rationale and potential clinical targets.
Topics: Aromatase; Aromatase Inhibitors; Female; Humans; Inositol; Polycystic Ovary Syndrome; Stereoisomeris | 2019 |
The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Topics: Adult; AMP-Activated Protein Kinases; Cells, Cultured; Endometrium; Enzyme Activation; Female; Gluco | 2020 |
Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.
Topics: Animals; Blood Glucose; Body Weight; Estrous Cycle; Female; Follicle Stimulating Hormone; Gene Expre | 2020 |
Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
Topics: Adult; Drug Therapy, Combination; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotr | 2020 |
Does inositol ratio orchestrate the fate of ovarian follicles?
Topics: Androgens; Female; Humans; Inositol; Ovarian Follicle; Polycystic Ovary Syndrome; Testosterone | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Effects of inositol and alpha lipoic acid combination for polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Topics: Drug Therapy, Combination; Female; Humans; Inositol; Meta-Analysis as Topic; Polycystic Ovary Syndro | 2020 |
D-Chiro-Inositol Treatment Affects Oocyte and Embryo Quality and Improves Glucose Intolerance in Both Aged Mice and Mouse Models of Polycystic Ovarian Syndrome.
Topics: Aging; Animals; Blastocyst; Cumulus Cells; Dihydrotestosterone; Disease Models, Animal; Female; Gene | 2020 |
Inositols: reflections on how to choose the appropriate one for PCOS.
Topics: Female; Humans; Inositol; Insulin Resistance; Metabolic Syndrome; Polycystic Ovary Syndrome; Vitamin | 2020 |
The efficacy of different insulin-sensitizing agents on treatment outcomes in patients with polycystic ovary syndrome who underwent in-vitro fertilization: A retrospective, record-based, comparative study.
Topics: Adult; Case-Control Studies; Cell Count; Chorionic Gonadotropin; Female; Fertilization in Vitro; Hum | 2021 |
Letter to "May myo-inositol and D-chiro-inositol (40:1) treatment be a good option on normal-weighted polycystic ovary syndrome patients without insulin resistance?"
Topics: Body Weight; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2021 |
PCOS and Inositols: Controversial Results and Necessary Clarifications. Basic Differences Between D-Chiro and Myo-Inositol.
Topics: Female; Humans; Inositol; Polycystic Ovary Syndrome | 2021 |
High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries.
Topics: Animals; Disease Models, Animal; Female; Humans; Inositol; Mice; Ovary; Polycystic Ovary Syndrome | 2021 |
The relevance of inositols treatment for PCOS before and during ART.
Topics: Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome; Proto-Oncogene Proteins c-a | 2021 |
[The myo-inositol is beneficial in the therapy of pregnancy with insulin-dependent type 2 diabetes and polycystic ovary syndrome].
Topics: Adult; Diabetes Mellitus, Type 1; Female; Humans; Infant, Newborn; Inositol; Polycystic Ovary Syndro | 2017 |
Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
Topics: Adolescent; Adult; Androstenedione; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, C | 2017 |
A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women.
Topics: Adult; Body Mass Index; Fasting; Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; | 2017 |
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Female; Humans; Inositol; Polycystic Ovary Syndrome | 2018 |
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic Ovary Syndrome | 2018 |
Ameliorative effect of myo-inositol on red blood cell alterations in polycystic ovary syndrome: in vitro study.
Topics: Adult; Erythrocytes; Female; Glutathione; Humans; Immunoglobulin G; Inositol; Phosphorylation; Polyc | 2018 |
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Clomiphene; Female; Humans; Inositol; Metformin; Polycystic Ovary Syndrome | 2018 |
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Clomiphene; Female; Humans; Inositol; Metformin; Polycystic Ovary Syndrome | 2018 |
Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Humans; Hyper | 2018 |
Inositol for women with polycystic ovary syndrome-possibly just better than placebo.
Topics: Female; Humans; Inositol; Ovulation Induction; Polycystic Ovary Syndrome; Vitamin B Complex | 2019 |
Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model.
Topics: Animals; Body Weight; Disease Models, Animal; Female; Granulosa Cells; Inositol; Light; Male; Mice, | 2019 |
Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome.
Topics: Acetylcysteine; Complementary Therapies; Dietary Supplements; Female; Humans; Infertility; Inositol; | 2019 |
Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Body Weight; Drug Therapy, Combination; Estradiol; Female; Folli | 2019 |
Why nutrition should be the first prescription.
Topics: Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Inositol; Polycystic Ovary Syndrome; Prem | 2018 |
Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Blood Glucose; Body Weight; Cohort Studies; Female; Hormones; Humans; Inositol; Polycystic Ov | 2019 |
Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.
Topics: Adult; Body Composition; Diet Therapy; Female; Folic Acid; Humans; Inositol; Inositol Phosphates; Me | 2019 |
Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Topics: Adult; Androstenedione; Drug Therapy, Combination; Estradiol; Female; Follicle Stimulating Hormone; | 2019 |
Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Female; Hirsutism; Humans; Inositol; Insulin Resistance; Organ Size; Ovary; | 2020 |
Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
Topics: Adult; Antioxidants; Body Mass Index; Body Weight; Combined Modality Therapy; Dietary Supplements; F | 2020 |
[Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Inositol; Lipid Metabolism; Lova | 2013 |
The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
Topics: Adult; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2013 |
Alterations in thyroid function among the different polycystic ovary syndrome phenotypes.
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Female; Hospitals, University; Humans; Hypoglycem | 2013 |
Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls.
Topics: Adult; Carbohydrate Epimerases; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndr | 2014 |
Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome.
Topics: Body Weight; C-Reactive Protein; Female; Glucose Tolerance Test; Gonadotropin-Releasing Hormone; Hum | 2014 |
[Statement of the Polish Gynecological Society on the application of myo-inozytol in patients with PCOS (polycystic ovary syndrome)].
Topics: Congresses as Topic; Female; Gynecology; Humans; Inositol; Inservice Training; Obstetrics; Ovulation | 2014 |
Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
Topics: Animals; Female; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Inosit | 2014 |
Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin.
Topics: Adult; Biomarkers; Female; Fertilization in Vitro; Follicular Fluid; Gonadotropins; Humans; Inositol | 2014 |
The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.
Topics: Adult; Anti-Mullerian Hormone; Female; Humans; Inositol; Menstrual Cycle; Menstruation Disturbances; | 2015 |
Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
Topics: Adult; Blood Glucose; Female; Folic Acid; Follicle Stimulating Hormone; Humans; Inositol; Luteinizin | 2015 |
Is it time to consider patients suffering from endometriosis-related infertility as "novel candidates" for targeted peri-conceptional D-chiro inositol supplementation? Hypothesis, rationale and some considerations.
Topics: Biomarkers; Female; Humans; Inositol; Metformin; Oxidative Stress; Polycystic Ovary Syndrome; Protei | 2015 |
"Empiric" inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects.
Topics: Female; Folic Acid; Humans; Inositol; Menstruation Disturbances; Ovary; Polycystic Ovary Syndrome; V | 2015 |
Authors' reply to: "Empiric" inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects.
Topics: Female; Folic Acid; Humans; Inositol; Menstruation Disturbances; Ovary; Polycystic Ovary Syndrome; V | 2015 |
Myo-inositol: with or without.
Topics: Carbohydrate Epimerases; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2015 |
d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Inositol; Menstruation Disturbances; M | 2015 |
Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
Topics: Congenital Abnormalities; Diabetes, Gestational; Female; Humans; Inositol; Insulin Resistance; Metab | 2015 |
The effect of FT500 Plus(®) on ovarian stimulation in PCOS women.
Topics: Adult; Antioxidants; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Follicular F | 2016 |
Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation?
Topics: Amenorrhea; Animals; Cadherins; Corpus Luteum; Cytoskeleton; Epithelial-Mesenchymal Transition; Fema | 2016 |
Inositols: from physiology to rational therapy in gynecological clinical practice.
Topics: Female; Genital Diseases, Female; Humans; Infertility, Female; Inositol; Polycystic Ovary Syndrome | 2016 |
Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
Topics: Acne Vulgaris; Adult; Drug Administration Schedule; Female; Hirsutism; Homeostasis; Humans; Inositol | 2009 |
[Effects of inositol on oocyte quality in patients affected with polycystic ovary syndrome].
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Folic Acid; Humans; Infertility, F | 2010 |
The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen.
Topics: Adult; Case-Control Studies; Chi-Square Distribution; Dietary Supplements; Female; Fertility Agents, | 2011 |
Polycystic ovary syndrome: a vitamin deficiency? Floating a new pathogenesis hypothesis.
Topics: Dietary Supplements; Female; Humans; Inositol; Polycystic Ovary Syndrome; Risk Factors; Treatment Ou | 2010 |
Myo-inositol products in polycystic ovary syndrome (PCOS) treatment: quality, labeling accuracy, and cost comparison.
Topics: Adult; Chromatography, High Pressure Liquid; Drug Costs; Drug Labeling; Female; Humans; Inositol; Po | 2011 |
Inositol effects on ovulation induction in patients with polycystic ovary syndrome.
Topics: Dietary Supplements; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; I | 2011 |
Comments on the role of inositol supplementation in patients with polycystic ovary syndrome.
Topics: Dietary Supplements; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; I | 2011 |
The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen.
Topics: Dietary Supplements; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; I | 2011 |
The D-chiro-inositol paradox in the ovary.
Topics: Female; Humans; Inositol; Insulin; Ovary; Ovulation; Polycystic Ovary Syndrome; Racemases and Epimer | 2011 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
Topics: Female; Humans; Inositol; Ovulation Induction; Polycystic Ovary Syndrome | 2011 |
[Myoinositol--alternative treatment of insulin resistance in adolescents].
Topics: Adolescent; Female; Humans; Inositol; Inositol Phosphates; Insulin; Insulin Resistance; Polycystic O | 2011 |
[Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol].
Topics: Adolescent; Adult; Drug Combinations; Endocrine System; Female; Folic Acid; Humans; Inositol; Polycy | 2012 |
Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Blood Pressure; Body Mass Index; Female; Glucose Tolerance | 2006 |
Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome.
Topics: Bacillus subtilis; Base Sequence; Biotransformation; Chromatography, High Pressure Liquid; Diabetes | 2006 |
Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism.
Topics: Adolescent; Adult; Body Mass Index; Case-Control Studies; Female; Glucose Tolerance Test; Greece; Hu | 2008 |
Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system.
Topics: Adult; Antibodies; Female; Humans; Inositol; Insulin; Insulin-Like Growth Factor I; Polycystic Ovary | 1998 |
Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Inositol Phosphat | 1998 |